Ivabradin Sandoz

Ivabradine, the active ingredient in Ivabradin Sandoz, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide from its EU‑origin manufacturing network. Our distribution adheres to stringent quality standards and regulatory requirements.

Ivabradin Sandoz acts on the cardiac If current to control heart rate in specific cardiovascular conditions. - Chronic stable angina: improves exercise tolerance by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: reduces heart rate, alleviating symptoms and decreasing hospitalization risk. - Patients intolerant to beta‑blockers: offers an alternative means of heart‑rate control without beta‑adrenergic blockade.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate slower than intended. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or tiredness. - Blurred vision.

Serious or Rare Side Effects: - Severe bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Symptomatic atrioventricular block. - Syncope (fainting). - Allergic reactions such as rash or angioedema.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Baseline heart rate assessment: ensure resting rate is ≥50 bpm before starting. - Severe hypotension: avoid use in patients with systolic BP <90 mmHg. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Sick sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradin Sandoz may interact with several concomitant medicines, influencing its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may markedly increase ivabradine levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may substantially reduce efficacy. - Other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Verapamil or diltiazem: moderate CYP3A4 inhibition can raise ivabradine concentrations. - CYP3A4‑modulating antidepressants (e.g., fluoxetine, sertraline): monitor heart rate and symptoms. - Antihypertensives: observe for additive blood‑pressure lowering effects.